Decision: Favourable

Study Title:

Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA

  • NREC Code:

    21-NREC-CT-038-NPC

  • Decision:

    Favourable

  • Meeting Date:

    21/07/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Professor Patrick Morris

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    Cancer Trials Ireland

Scroll to Top
Skip to content